The FDA recently approved sofosbuvir as a once-daily oral treatment for hepatitis C, according to a Gastroenterology & Endoscopy News report.
Sofosbuvir is a nucleotide analog polymerase inhibitor, the first FDA-approved all-oral treatment for patients with HCV genotypes 2 or 3.
The drug received approval shortly after simeprevir, an Olysio, Janssen Therapeutics drug for patients with HCV genotype 1.
Sofosbuvir is a product of Gilead Sciences.
More Articles on Supply Chain:
FDA Gives 510(k) Clearance to Therapy Cool Flex Ablation Catheter
FDA Issues Draft Guidance on Custom Device Exemption Implementation
FDA Approves First Gel Sealant for Leaking Cornea After Cataract Surgery